Total Neoadjuvant Therapy in Rectal Cancer in the Community Setting | 2022 Evolution Conference

Many larger academic cancers now use total neoadjuvant therapy, or TNT, as a treatment option for patients with locally advanced rectal cancer. In this session, Dr Laura Van Metre Baum from Yale Cancer Center discusses some of the unique aspects of using the TNT approach for rectal cancer in the community setting.
To obtain credit for this CME activity you must watch the full 2022 Evolution Conference Playlist. Information on obtaining CME/CE Credits and MOC points can be found in the playlist description.

[@khaliddurrani6432]

To conclude for T1,2 rectal tumors short course radiation is appropriate, but for stage 3 or T4 tumors long course CRt is preferred. I either case surgery is performed 8-10 weeks after the last dose of radiation and chemo is given peri-operatively. TNT implies chemo radiation and full course of chemo prior to TME. OPRA trial shows slight advantage of chemo ( consolidation) after radiation rather than induction chemo.

[@michaels908]

I'm starting immunotherapy with Keytruda beginning on March 4th. I have stage 4 rectal cancer, with a miss-matched mutant tumors. Eighteen patients were involved in a clinical trial at Memorial Sloan Kettering Cancer Center one year ago and they had a 100% success rate. All their tumors vanished. What better odds can I get.

[@davidgardner1675]

This your LIFE make it happen